Pipeline

In addition to TVI-Brain-1, TVAX® has created a high-value pipeline of therapeutic candidates targeting a broad range of cancers.  This includes TVI-Kidney-1, which like TVI-Brain-1, is supported by positive Phase 2 clinical data, as well as extensive preclinical and Phase 1 safety studies.  Also, similar to TVAX’s lead brain cancer program, the company has been authorized by FDA to initiate pivotal Phase 3 clinical trials for TVI-Kidney-1 to support its potential FDA approval.  

The company’s additional pipeline programs are supported by extensive proof-of-concept and safety data highlighting TVAX Immunotherapy®’s potential to treat several other cancers.